ACST - Acasti Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9451
-0.0059 (-0.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9510
Open0.9319
Bid0.9320 x 1000
Ask0.9452 x 800
Day's Range0.9300 - 0.9500
52 Week Range0.4300 - 1.8000
Volume175,845
Avg. Volume290,454
Market Cap72.796M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-1.2240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s two on-going Phase 3 TRILOGY trials (TRILOGY 1 and TRILOGY 2) have exceeded a combined 89% patient randomization, and more than 40% of the patients in both trials have completed their 6-month treatment plan. With the expected approximate 1 month of data clean-up following the “last patient out”, topline results for TRILOGY 1 are expected in December. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “We are very pleased to announce that our two TRILOGY Phase 3 trials are proceeding well and according to plan.

  • GlobeNewswire18 days ago

    Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

    Further validates prior study results demonstrating that the bioavailability of CaPre is significantly better than LOVAZA when taken with a low-fat meal LAVAL, Québec,.

  • GlobeNewswire24 days ago

    Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

    Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company’s President and CEO, Jan D’Alvise, is scheduled to present at the 2019 Spring Investor Summit on Tuesday, April 2, 2019 at 1:30 pm Eastern Time at The Essex House in New York City. The Spring Investor Summit will take place in New York City at the Essex House on April 1st and 2nd.

  • GlobeNewswirelast month

    Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

    Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body.

  • GlobeNewswire2 months ago

    Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announces it has been recognized  by the TSX Venture Exchange  in its “2019 Venture 50,” a ranking of the strongest companies on TSX Venture Exchange by share price, trading volume and market capitalization.

  • Associated Press2 months ago

    Acasti: Fiscal 3Q Earnings Snapshot

    The Laval, Quebec-based company said it had a loss of 5 cents per share. The company's shares closed at 91 cents. A year ago, they were trading at $1.02. _____ This story was generated by Automated Insights ...

  • GlobeNewswire2 months ago

    Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

    LAVAL, Québec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal third quarter ended December 31, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We continue to make rapid progess on our TRILOGY Phase 3 trials, and based on current trends we remain on track to report topline results by the end of this year.

  • GlobeNewswire2 months ago

    Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

    Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, February 14, 2019 to discuss the Company’s financial results for the fiscal third quarter ended December 31, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 866-682-6100 for U.S. callers or +1 862-298-0702 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Looking To Set January Highs

    CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.

  • GlobeNewswire3 months ago

    Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

    LAVAL, Québec, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced a Certificate for a European Patent has been issued by the European Patent Office. Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “This is an important milestone for Acasti, as the allowance of a patent in a major jurisdiction such as Europe further strengthens and expands the Company’s intellectual property portfolio.

  • GlobeNewswire4 months ago

    Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients ( 20%) Have Completed Their 6 Month Treatment Plan

    LAVAL, Québec, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the two Phase 3 TRILOGY trials have now exceeded 65% patient randomization, and more than 100 patients have completed their 6 month treatment plan. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We are pleased to announce that more than 20% of patients in the TRILOGY program have already completed their 6 month treatment plans. Additionally, Acasti Pharma today announced that on December 26, 2018, it received written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) for failing to maintain a minimum bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) – bid price (the “Minimum Bid Price Rule”).

  • Generic Industry on Path to Recovery: 3 Hot Picks for 2019
    Zacks4 months ago

    Generic Industry on Path to Recovery: 3 Hot Picks for 2019

    The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

  • GlobeNewswire4 months ago

    Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

    LAVAL, Québec, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced it has reached the enrollment targets for its TRILOGY phase 3 trials.  In total, over 1,450 patients have been enrolled at 150 clinical sites across the U.S., Canada and Mexico. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “We are pleased to report we have achieved our planned enrollment targets on schedule.  Additionally, as of December 19, 2018, more than 60% of the required total of 500 patients for the two studies have been randomized.  Additional patients may still be added to the TRILOGY program as needed early next year to achieve final randomization targets.

  • ACCESSWIRE5 months ago

    Acasti Pharma to Present at the 11th Annual LD Micro Main Event

    Laval, Québec / ACCESSWIRE / November 27, 2018 / Acasti Pharma Inc. (ACST) (ACST) (the "Company" or "Acasti Pharma"), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the Company is scheduled to present at the 11th annual LD Micro Main Event on Wednesday, December 5 at 3:00 PM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Jan D'Alvise, President and Chief Executive Office, will be presenting, as well as meeting with investors.

  • Associated Press5 months ago

    Acasti: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Laval, Quebec-based company said it had a loss of 47 cents. Losses, adjusted for non-recurring costs and amortization costs, came to 19 cents per share. The company's shares closed ...

  • GlobeNewswire5 months ago

    Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

    LAVAL, Québec, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the fiscal second quarter ended September 30, 2018. Jan D’Alvise, president and CEO of Acasti Pharma, commented, “Following our recent capital raises in the U.S. and Canada, I am pleased to report as of November 1, we had over $52 million of cash on hand.

  • GlobeNewswire5 months ago

    Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

    Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host a conference call at 11:00 AM Eastern Time on Wednesday, November 14, 2018 to discuss the Company’s financial results for the fiscal second quarter ended September 30, 2018, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers, or on the Company’s News and Investors section of the website: https://www.acastipharma.com/investors/.

  • ACCESSWIRE6 months ago

    Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

    NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Benzinga6 months ago

    The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) AstraZeneca plc (NYSE: AZN ) Bausch Health Companies ...